Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | Ropeginterferon Alfa-2b | FDA US | Essential Thrombocythemia | The treatment of adults with essential thrombocythemia. | ORIGBLA761166 | approved | openfda |
| Nov 12, 2021 | Pralsetinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GAVRETO (DIN 02517590) under ATC L01EX23 PRALSETINIB. Indications are not published in the Drug Product Database —… | DIN02517590 | withdrawnsource: Cancelled Post Marketsince Feb 26, 2025 | health-canada-dpd |
| Nov 9, 2021 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BAMBEVI (DIN 02520737) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02520737 | approvedsource: Marketed | health-canada-dpd |
| Nov 9, 2021 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BAMBEVI (DIN 02520729) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02520729 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 29, 2021 | Asciminib | FDA US | cancer not stated in this record | SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2021 | Zanubrutinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-08-31 (see label) | SUPPLNDA213217 | approved | openfda |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| ORIGNDA215358 |
| approved |
| openfda |
| Oct 29, 2021 | Asciminib | FDA US | cancer not stated in this record | SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia… | ORIGNDA215358 | approved | openfda |
| Oct 26, 2021 | Polatuzumab Vedotin | Health Canada CA | cancer not stated in this record | Marketed in Canada as POLIVY (DIN 02515431) under ATC L01FX14 POLATUZUMAB VEDOTIN. Indications are not published in the Drug Product… | DIN02515431 | approvedsource: Marketed | health-canada-dpd |
| Oct 22, 2021 | Sotorasib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUMAKRAS (DIN 02520095) under ATC L01XX73 SOTORASIB. Indications are not published in the Drug Product Database — see… | DIN02520095 | approvedsource: Marketed | health-canada-dpd |
| Oct 22, 2021 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPECITABINE (DIN 02514990) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02514990 | approvedsource: Marketed | health-canada-dpd |
| Oct 22, 2021 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPECITABINE (DIN 02514982) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02514982 | approvedsource: Marketed | health-canada-dpd |
| Oct 21, 2021 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-METHOTREXATE (DIN 02509067) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02509067 | approvedsource: Marketed | health-canada-dpd |
| Oct 15, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-15 (see label) | SUPPLBLA761034 | approved | openfda |
| Oct 13, 2021 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-13 (see label) | SUPPLBLA125514 | approved | openfda |
| Oct 13, 2021 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-13 (see label) | SUPPLBLA125514 | approved | openfda |
| Oct 12, 2021 | Abemaciclib | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-12 (see label) | SUPPLNDA208716 | approved | openfda |
| Oct 12, 2021 | Abemaciclib | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-12 (see label) | SUPPLNDA208716 | approved | openfda |
| Oct 12, 2021 | Abemaciclib | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-12 (see label) | SUPPLNDA208716 | approved | openfda |
| Oct 7, 2021 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as KANJINTI (DIN 02518244) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02518244 | approvedsource: Marketed | health-canada-dpd |
| Oct 7, 2021 | Tepotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEPMETKO (DIN 02516322) under ATC L01EP02 TEPOTINIB. Indications are not published in the Drug Product Database — see… | DIN02516322 | approvedsource: Marketed | health-canada-dpd |
| Oct 7, 2021 | Dexamethasone | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-07 (see label) | SUPPLNDA208742 | approved | openfda |
| Oct 6, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-06 (see label) | SUPPLBLA761034 | approved | openfda |
| Oct 5, 2021 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as MINT-CAPECITABINE (DIN 02508028) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02508028 | approvedsource: Marketed | health-canada-dpd |
| Oct 4, 2021 | Venetoclax | FDA US | cancer not stated in this record | Efficacy supplement 2021-10-04 (see label) | SUPPLNDA208573 | approved | openfda |
| Oct 4, 2021 | Sertraline | FDA US | cancer not stated in this record | Sertraline Hydrochloride (HCl) Capsules is indicated for the treatment of the following [see Clinical Studies ( 14 )] : Major depressive… | ORIGNDA215133 | approved | openfda |
| Oct 4, 2021 | Sertraline | FDA US | cancer not stated in this record | Sertraline Hydrochloride (HCl) Capsules is indicated for the treatment of the following [see Clinical Studies ( 14 )] : Major depressive… | ORIGNDA215133 | approved | openfda |
| Sep 23, 2021 | Nilotinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-09-23 (see label) | SUPPLNDA022068 | approved | openfda |
| Sep 23, 2021 | Nilotinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-09-23 (see label) | SUPPLNDA022068 | approved | openfda |
| Sep 22, 2021 | Imatinib | EMA EU | cancer not stated in this record | Imatinib Koanaa is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl)… | centralisedEMEA/H/C/005595 | withdrawnsince Aug 31, 2023 | ema |
| Sep 22, 2021 | Ruxolitinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-09-22 (see label) | SUPPLNDA202192 | approved | openfda |
| Sep 21, 2021 | Ruxolitinib | FDA US | cancer not stated in this record | the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and… | ORIGNDA215309 | approved | openfda |
| Sep 20, 2021 | Tisotumab Vedotin | FDA US | Malignant Cervical Neoplasm | TIVDAK ® is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after… | ORIGBLA761208 | approved | openfda |
| Sep 17, 2021 | Cabozantinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-09-17 (see label) | SUPPLNDA208692 | approved | openfda |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514796) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514796 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514788) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514788 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514761) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514761 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514753) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514753 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514745) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514745 | approvedsource: Marketed | health-canada-dpd |
| Sep 16, 2021 | Dasatinib (dasatinib (s)-Propylene Glycol) | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-DASATINIB (DIN 02514737) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product… | DIN02514737 | approvedsource: Marketed | health-canada-dpd |
| Sep 14, 2021 | Zanubrutinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-09-14 (see label) | SUPPLNDA213217 | approved | openfda |
| Sep 9, 2021 | Talazoparib | FDA US | cancer not stated in this record | Efficacy supplement 2021-09-09 (see label) | SUPPLNDA211651 | approved | openfda |
| Sep 7, 2021 | Apalutamide | FDA US | cancer not stated in this record | Efficacy supplement 2021-09-07 (see label) | SUPPLNDA210951 | approved | openfda |
| Aug 31, 2021 | Treosulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRECONDYV (DIN 02517388) under ATC L01AB02 TREOSULFAN. Indications are not published in the Drug Product Database —… | DIN02517388 | approvedsource: Marketed | health-canada-dpd |
| Aug 31, 2021 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-08-31 (see label) | SUPPLBLA125514 | approved | openfda |
| Aug 31, 2021 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-08-31 (see label) | SUPPLBLA125514 | approved | openfda |
| Aug 30, 2021 | Sunitinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-08-30 (see label) | SUPPLNDA021938 | approved | openfda |
| Aug 30, 2021 | Bacillus Calmette-Guérin (bcg) - Strain Russian Bcg-I | Health Canada CA | cancer not stated in this record | Marketed in Canada as VERITY-BCG (DIN 02508613) under ATC L03AX03 BCG VACCINE. Indications are not published in the Drug Product Database —… | DIN02508613 | approvedsource: Marketed | health-canada-dpd |
| Aug 26, 2021 | Tafasitamab | EMA EU | Diffuse Large B-Cell Lymphoma | Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or… | centralisedEMEA/H/C/005436 | approved | ema |
| Aug 25, 2021 | Ivosidenib | FDA US | cancer not stated in this record | Efficacy supplement 2021-08-25 (see label) | SUPPLNDA211192 | approved | openfda |